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Abstract 
An electrochemical method for the determination of the anticancer platinum drug carboplatin using a DNA-modified electrode was 
developed. This electrode was successfully used for the electrochemical determination of carboplatin in serum samples of patients with 
ovarian cancer undergoing treatment. The electrochemical results clearly demonstrated that, for low concentrations, carboplatin interacts 
preferentially with adenine rather than guanine groups in the DNA and they can contribute to clarifying the mechanisms of interaction of 
platinum anticancer drugs with DNA. The pharmacokinetics c o r m  ondIng to the administration of the drug was followed 
electrochemically and the detection limit in serum samples was 5.7 x 10 M. Due to a similar mechanism of reaction with DNA other 
platinum anticancer drugs can be determined by this method. 
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1. Introduction 
The objective of our work was to develop an electrochemical 
method for determination of anticancer platinum drugs, namely 
carboplatin. The anticancer activity of eis-dichloroamine- 
platinum(i1) was discovered in 1969 [ I ] ,  and successes with this 
compound were achieved in the treatment of testicular and 
ovarian cancers, both with cisplatin alone and in combination 
with other drugs. However, because of its toxic effects, more 
than 300 other platinum complexes were examined in the 1970s. 
Carboplatin, (cis-diammine-1,l-cyclobutanedicarboxylate) plat- 
inum(ir) was selected for preclinical studies and it seems that less 
toxic effects may be due to higher solubility in water (21. 
Several analytical methods have been described for the 
determination of cisplatin in biological matrices using HPLC 
with spectrometric detection [3-91 or LC with electrochemical 
detection systems [lo-171; the electrochemical behavior of 
cisplatin at dropping mercury [18], modified carbon paste and 
platinum [ 191 electrodes was also studied. However, there are 
fewer studies concerning the determination of carboplatin. 
Direct electrochemical determination is difficult because it does 
not have high electrochemical activity [ I  1, 12, 151. Only one 
anodic peak can be observed at very high potentials [20]. 
Because of this, derivatization procedures are carried out 
followed by analytical determination with spectrometric [6] or 
electrochemical [ l  11 detection. In the latter case, carboplatin is 
converted to cisplatin which is then detected electrochemically. 
This article describes analytical quantification of carboplatin 
in serum samples from women patients with ovarian cancer 
undergoing treatment with this drug, by using a DNA-modified 
glassy carbon electrode. 
2. Experimental 
Calf thymus DNA (sodium salt, type I), adenosine 5'- 
monophosphate and guanosine 5'-monophosphate were 
obtained from Sigma Chemical Co. and were used without 
further purification. Carboplatin was from David Bull 
Laboratories ( I  50mg/15 mL). Preparation of single stranded 
DNA (ss DNA) was done by the following procedure. An 
accurately weighed sample of approximately 3 mg of DNA was 
treated with 0.5 mL of pure perchloric acid. After dissolution, 
0.5 mi, of 9 M NaOH was then added to neutralize the solution 
followed by 9mL of pH 4.6 acetate buffer. 
Adenosine 5'-monophosphate and guanosine 5'-mOnO- 
phosphate solutions of 1 mM concentration were prepared by 
dissolution of appropriate weight in a solution containing 40 mL 
of 4.5 pH acetate buffer with 5 mL of pure perchloric acid and 
5 mL of 9 M NaOH. Acetate buffer solutions of ionic strength 
0.1 were used in all experiments at pH 4.6, and were prepared 
using analytical grade reagents and purified water from a 
Millipore Milli-Q system. 
Serum samples from patients undertaking a carboplatin 
(CBDCA) treatment, were provided by the Oncology Unit, 
Gynaecology Service, University Hospital of Coimbra, and 
were deproteinized by addition of 10% trichloroacetic acid (1: 1 
v./v.). After protein precipitation, the samples were centrifuged 
during 5min at 2500rpm. Carboplatin was determined at 
different times after the administration of the drug in the 
deproteinized serum samples. Serum blank samples were 
collected before the administration of the drug. The electro- 
chemical cell contained 3.0mL of 78 pg/mL ssDNA solution in 
acetate buffer electrolyte at pH 4.6 to which was added 500 pL 
of the deproteinized serum samples followed by standard 
additions of 20-50 pL of 0.027 M carboplatin in the experi- 
ments with ssDNA and 50pL of 0.5niM carboplatin in the 
experiments with adenosine. The same conditions were used in 
the electrochemical cell when 0.1 mM of adenosine 5'-nlOnO- 
phosphate or 0.1 mM of guanosine 5'-inonophosphate was used 
instead of ssDNA. 
The working electrode was glassy carbon modified with 
adsorbed DNA, the counter electrode was a Pt wire, and the 
reference electrode was a SCE, all contained in a one- 
compartment cell. The DNA-modified electrode was prepared 
by covering a glassy carbon electrode (Tokai, GC20, area 
0.07 cm2) with 3 mg of DNA dissolved in 80 pL of pH 4.5 acetate 
buffer and leaving the electrode to dry. After drying, the 
electrode was immersed in acetate buffer solution and a constant 
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Fig. 1. Differential pulse voltammograms using a DNA-modified 
electrode of a solution of ssDNA, 78 pg/mL plus carboplatin concentra- 
tions of: I )  zero; 2) 84.4pM; 3) 161 pM; 4) 236pM in pH 4.6 acetate 
buffer containing 0.5 mL of 5% trichloroacetic acid. 5 )  supporting 
electrolyte voltammogram. Pulse amplitude SO mV, pulse width SO ms, 
scan rate 5 mV s-I. 
potential of + 1.4V applied during 5 minutes. Then it was 
transferred to a solution containing single stranded DNA. 
Differential pulse voltammograms were recorded, in order to 
evaluate the stabiblity of the DNA-modified glassy carbon, in 
the range 0 to + 1.4V. 
Differential pulse voltammograms were recorded using a 
pAutolab potentiostat/galvanostat running with GPES version 
3 software, from Eco-Chemie, Utrecht, The Netherlands. The 
differential pulse voltammetry conditions were: pulse amplitude 
50 mV, pulse width 70 ms and scan rate 5 mV s- '. 
3. Results and Discussion 
Platinum compounds bind covalently to D N A  with cross 
links between two bases on opposite strands of the D N A  helix 
and intrastrand cross links between two bases on the same DNA 
strand. The latter seems to  be responsible for their antitumor 
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Fig. 2. Calibration plot for the decrease in the adenine (B) and guanine 
(0) peak current corresponding to the addition of carboplatin to a 78 pg/ 
mL solution of ssDNA in pH 4.6 acetate buffer containing 0.5 mL of 5% 
trichloroacetic acid. 
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Fig. 3. Differential pulse voltammograms using a DNA-modified 
electrode of a solution of ssDNA, 78 pg/mL and 400wL of serum from 
a patient plus carboplatin concentrations of: I )  zero; 2) 0.39mM; 3 )  
1.1 mM; 4) 1.5mM; in pH 4.6 acetate buffer containing 0.5 mL of 5% 
trichloroacetic acid. Pulse amplitude 50 mV, pulse width SOms, scan rate 
~ r n ~ s ~ ' .  
activity [21]. It was shown that these reactions occur preferen- 
tially with the N7 atoms of guanine [2 1-25], 
Previous studies of single stranded DNA (ssDNA) electro- 
oxidation showed two peaks that are identified as the oxidation 
peaks of guanine ( + 0.87 V) and adenine ( + 1.12 V) groups [26]. 
It is known that carboplatin binds covalently with DNA and so 
it seemed quite clear that it could be possible to develop an 
indirect analytical method to determine platinum compounds 
with antitumor activity by measuring this interaction. Thus a 
DNA-modified glassy carbon electrode was prepared and 
conditioned as  described in the experimental section. After 
conditioning, stable oxidation currents were observed for the 
peaks corresponding to guanine and adenine when the electrode 
was placed in a ssDNA solution. Carboplatin was added to the 
solution containing ssDNA and, for the concentrations used, 
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Fig. 4. Calibration plots for the decrease in the adenine (B) and guanine 
(0) peak current corresponding to the addition of carboplatin to a 78 pg/ 
mL solution of ssDNA and 400pL of serum from a patient in pH 4.6 
acetate buffer containing 0.5mL of 5% trichloroacetic acid. 
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Fig. 5. Pharmacokinetic curves obtained using a DNA-modified 
electrode in a solution of ssDNA with serum, for two patients 
undertaking treatment with carboplatin. 
the interaction with adenine was very clear from the results 
obtained for three consecutive additions of carboplatin as 
shown in the differential pulse voltammograms of Figure 1. The 
linear range of current decrease is 7.7 x M. 
There is a decrease in the oxidation current of adenine with 
increasing the concentration of the antineoplastic drug in 
solution while the guanine oxidation currents only decrease 
slightly. This is illustrated in Figure 2. The values on the y axis 
are the variation in current corresponding to the difference 
betweeen the current observed initially, before the addition of 
carboplatin, and after the addition of carboplatin (A1 = finilia, 
~ Icarb). The response range for the determination of carboplatin 
in serum samples by the standard addition method using ssDNA 
solutions was in the range 6.5 x 10 M .  No 
surface fouling by serum was observed. 
Real samples were then employed to test the method. Serum 
samples were collected from two patients undertaking carbo- 
platin treatment at different times after the administration of the 
drug. The experiments were performed in the conditions 
described in the experimental section. Llifferential pulse 
voltammograms, Figure 3, showed, besides the usual peaks for 
guanine and adenine, a new peak at a potential of + 0.43 V that 
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Fig. 6. Calibration plots for the decrease in the adenosine (W) or 
guanosine (0) peak current corresponding, respectively, to the addition 
of carboplatin to a solution of the nucleotides adenosine 5’-mOnO- 
phosphate or guanosine 5’-monophosphate in pH 4.6 acetate buffer 
containing 0.5mL of 5% trichloroacetic acid. 
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Fig. 7. Calibration plots for the decrease in the adenosine peak current 
corresponding to the standard addition of carboplatin to a 0.1 mM 
solution of the nucleotide adenosine 5’-monophosphate and 500 pL of 
serum from a patient in acetate buffer pH 4.6 containing 0.5mL of 5% 
trichloroacetic acid: serum of the patient (m) before and (0) 8 h after 
administration of carboplatin. 
corresponds to uric acid existing in serum and coming from 
normal human metabolism. The calibration plot is presented in 
Figure 4 and, again, the interaction with adenine is much higher 
than with guanine. The evaluation of the pharmacokinetics of 
the drug during treatment is in Figure 5 ,  for two patients, and an 
exponential type decay was observed as expected. It is 
interesting to note that the levels of carboplatin in the serum 
vary slightly between patients which is not surprising and is due 
to different stages of the disease and individual reaction to the 
treatment. 
Our results, obtained using electrochemical methods, clearly 
indicate preferential interaction of carboplatin with the adenine 
groups in the ssDNA solution, during the time scale of the 
voltammetric experiments, i.e., less than 10 min, and almost no 
reaction with guanine groups. Results described by previous 
workers using NMR and longer reaction times [21-241, showed 
a preferential interaction of carboplatin with the guanine 
groups. In order to clarify this apparent contradiction we 
studied the interaction of carboplatin with the nucleotides 
adenosine 5’-monophosphate and guanosine 5’-monophosphate 
separately. The concentrations of the nucleotides were 0.1 mM 
signifying a small molar carboplatin/nucleotide ratio. 
From the results obtained, Figure 6, the conclusion is that for 
low concentrations of carboplatin (w 10-‘M) there is a 
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Fig. 8. Pharmacokinetic curve obtained using a DNA-modified electrode 
in a solution of the nucleotide adenosine 5’-monophosphate with serum, 
for a patient undertaking treatment with carboplatin. 
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undergoing treatment with carboplatin. The pharmacokinetics 
corresponding to the administration of the drug can be followed 
by electrochemical methods and the detection limit in serum 
samples is 5.7 x 10 ‘ M. Other platinum anticancer drugs can be 
determined by this method but this does not create problems of 
selectivity since they will not be given simultaneously to the 
patient and the electrochemical method can always be used in a 
flow system in conjunction with HLPC separation. Besides the 
electroanalytical merits of this method it is clearly demonstrated 
that, for low concentrations, carboplatin interacts preferentially 
with adenine rather than guanine groups in the DNA and that 
electrochemical methods can contribute to clarifying the 
mechanisms of interaction of platinum anti-cancer drugs with 
DNA. 
preferential interaction with adenosine which is proportional to 
concentration and that saturates at higher concentrations. The 
shape of this plot suggests the formation of a complex between 
carboplatin and adenosine. The guanosine-carboplatin interac- 
tion for low concentrations of carboplatin is much less but 
increases steadily even at higher concentrations where the 
interaction with adenosine is not increasing measurably. 
Considering that previous researchers [21-241, mainly because 
of the specifications of the methods they were using, always used 
concentrations of carboplatin three orders of magnitude higher, 
10 2-10-3M, there is, effectively, no discrepancy with our 
results. It also shows that the electrochemical methods can 
throw light on this type of mechanism as they enable much 
lower concentrations of the analytes to be used. In fact, the 
linear response range for the determination of carboplatin by 
the standard addition method using the nucleotide adenosine 5’- 
monophosphate solution in aqueous solution or in serum 
samples is in the range of 5.7 x lo-‘ M to 4.0 x lo-’ M. 
Instead of using the nucleotides adenosine 5’-monophosphate 
or guanosine 5’-monophosphate we also did the same experi- 
ments for carboplatin with the free bases guanine and adenine. 
However, no linear relationship between the decrease in the 
oxidation currents with increasing concentration of carboplatin 
was observed meaning that other groups are involved in the 
interaction reaction and contribute to the stabilization of the 
products. 
After these experiments it seemed that in order to determine 
carboplatin in serum samples of patients with cancer disease it 
was not necessary to quantify the interaction with ss DNA as we 
could easily use thc nucleotide adenosine 5’-monophosphate. 
This is very important as it is much less expensive than ssDNA, 
and simplifies HPLC separation used in conjunction with 
electrochemical detection. The stability and reproducibility of 
the adenine peak without the drug using the DNA-modified 
glassy carbon electrode was excellent. 
The DNA-modified electrode was used to determine the 
concentration of carboplatin in serum samples of a third patient 
following administration of carboplatin using the standard 
addition method and following interaction with the nucleotide 
adenosine 5’-nionophosphate. To determine the linear response 
range in the biological matrix, a calibration plot done using the 
nucleotide adenosine 5’-monophosphate solution plus serum 
sample that was collected before the administration of the drug, 
Figure 7, and standard addition was used to determine the 
concentration of carboplatin containing serums collected at 
different times after administration of the drug. 
The pharmacokinetic curve is presented in Figure 8 and 
shows that in a 72h period the concentration of the drug 
decreased exponentially with time as expected. However, for 
more than 72 h after administration of the drug the concentra- 
tion of carboplatin in the serum samples is lower then the 
detection limit of 5.7 x 10 ‘ M and could not be determined. 
4. Conclusions 
The DNA-modified electrode can be used for electrochemical 
determination in serum samples of patients with ovarian cancer 
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